肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2009年
5期
338-340
,共3页
雒洪志%黄宗海%余元龙%陈宏%邓辉洲
雒洪誌%黃宗海%餘元龍%陳宏%鄧輝洲
락홍지%황종해%여원룡%진굉%산휘주
药物植入物%胃肿瘤%外科手术
藥物植入物%胃腫瘤%外科手術
약물식입물%위종류%외과수술
Drug implants%Stomach neoplasms%Surgical procedures operation
目的 探讨氟尿嘧啶植入剂在Ⅲ期胃癌患者根治术中应用的临床疗效.方法 分析中山市人民医院1999年1月至2002年12月收治的200例Ⅲ期胃癌根治术患者(120例患者术中使用氟尿嘧啶植入剂)的一般情况及生存情况,观察氟尿嘧啶植入剂在胃癌患者根治术中应用的临床疗效.结果 两组在体重(P=0.041)、血红蛋白(P=0.024)、血小板(P=0.017)及肿瘤标志物CEA(P=0.001)、CA199(P=0.003)之间差异有统计学意义.治疗组恶心、呕吐的发生率(28%)高于对照组(17%.P=0.006);两组骨髓抑制(P=0.81)、腹泻(P=0.72)、肝功能损害(P=0.97)及肾功能损害(P=0.20)的发生率差异无统计学意义.5年累积生存率治疗组(45%)高于对照组(15%,P=0.002).结论 胃癌根治术中应用氟尿嘧啶植入剂可显著提高患者的临床疗效.
目的 探討氟尿嘧啶植入劑在Ⅲ期胃癌患者根治術中應用的臨床療效.方法 分析中山市人民醫院1999年1月至2002年12月收治的200例Ⅲ期胃癌根治術患者(120例患者術中使用氟尿嘧啶植入劑)的一般情況及生存情況,觀察氟尿嘧啶植入劑在胃癌患者根治術中應用的臨床療效.結果 兩組在體重(P=0.041)、血紅蛋白(P=0.024)、血小闆(P=0.017)及腫瘤標誌物CEA(P=0.001)、CA199(P=0.003)之間差異有統計學意義.治療組噁心、嘔吐的髮生率(28%)高于對照組(17%.P=0.006);兩組骨髓抑製(P=0.81)、腹瀉(P=0.72)、肝功能損害(P=0.97)及腎功能損害(P=0.20)的髮生率差異無統計學意義.5年纍積生存率治療組(45%)高于對照組(15%,P=0.002).結論 胃癌根治術中應用氟尿嘧啶植入劑可顯著提高患者的臨床療效.
목적 탐토불뇨밀정식입제재Ⅲ기위암환자근치술중응용적림상료효.방법 분석중산시인민의원1999년1월지2002년12월수치적200례Ⅲ기위암근치술환자(120례환자술중사용불뇨밀정식입제)적일반정황급생존정황,관찰불뇨밀정식입제재위암환자근치술중응용적림상료효.결과 량조재체중(P=0.041)、혈홍단백(P=0.024)、혈소판(P=0.017)급종류표지물CEA(P=0.001)、CA199(P=0.003)지간차이유통계학의의.치료조악심、구토적발생솔(28%)고우대조조(17%.P=0.006);량조골수억제(P=0.81)、복사(P=0.72)、간공능손해(P=0.97)급신공능손해(P=0.20)적발생솔차이무통계학의의.5년루적생존솔치료조(45%)고우대조조(15%,P=0.002).결론 위암근치술중응용불뇨밀정식입제가현저제고환자적림상료효.
Objective To investigate the therapeutic effects of fluorouracil implants in Stage Ⅲgastric carcinoma patients after radical gastreetomy. Methods The general state of health and cumulative survival of 200 stage Ⅲ gastric carcinoma patients undergone radical gastrectomy from January, 1999 to, December 2002 in the People's Hospital of Zhongshan City were analyzed, in which only 120 patients administrated fluorouracil implants during radical gastreetomy. The therapeutic effects of fluorouracil implants in stage Ⅲ gastric carcinoma patients after radical gastrectomy were observed. Results The differences of weight (P = 0.041), HGB(P =0.024), Plt(P =0.017), CEA(P =0.001), CA19-9(P =0.003) were significant between two groups. The incidence rate of nausea/emesis in group T (28 %) was higher than that in group O(17 %, P = 0.006), and incidence rates of myelosuppression(P =0.81), diarrhea(P =0.72), hepatic function lesion(P =0.97) and renal function lesion(P =0.20) were no significant. The cumulative 5-year survival rate of group T(45 %) was higher than that in group O (15 %, P =0.002). Conclusion Fluorouracil implants can improve the therapeutic effects on gastric carcinoma patients undergone radical gastrectomy.
